# EDGAR Filing Document

**Accession Number:** 0002133217
**File Stem:** 0001213900-26-064484
**Filing Date:** 2026-6
**Character Count:** 10278
**Document Hash:** 65ba923d554cc17b152b8e2762d1340e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-064484.hdr.sgml**: 20260603

**ACCESSION NUMBER**: 0001213900-26-064484

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260603

**DATE AS OF CHANGE**: 20260603

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PSYENCE BIOMEDICAL LTD.
- **CENTRAL INDEX KEY:** 0001985062
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94325
- **FILM NUMBER:** 261059218

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
- **BUSINESS PHONE:** 27744604171

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 121 RICHMOND STREET WEST PENTHOUSE
- **STREET 2:** SUITE 1300
- **CITY:** TORONTO
- **PROVINCE COUNTRY:** A6
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Psyence Labs Ltd
- **CENTRAL INDEX KEY:** 0002133217

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1115

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 159 MAIN STREET
- **STREET 2:** PO BOX 2132, 1ST FLOOR, IRVINES PLACE
- **CITY:** ROAD TOWN
- **NON US STATE TERRITORY:** TORTOLA
- **PROVINCE COUNTRY:** D8
- **ZIP:** VG1110
- **BUSINESS PHONE:** 000-000-0000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 159 MAIN STREET
- **STREET 2:** PO BOX 2132, 1ST FLOOR, IRVINES PLACE
- **CITY:** ROAD TOWN
- **NON US STATE TERRITORY:** TORTOLA
- **PROVINCE COUNTRY:** D8
- **ZIP:** VG1110

## Exhibit 99.3

**SCHEDULE I**

**DIRECTORS AND EXECUTIVE OFFICERS OF PSYENCE LABS LTD.**

The following table sets forth the name, present principal occupation or employment, business address, and citizenship of each director and executive officer of the Reporting Person..

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Position with PsyLabs / Principal Occupation** | &nbsp;&nbsp;**Business Address** | &nbsp;&nbsp;**Citizenship** |
| &nbsp;&nbsp;CONTROL SERVICES CORP. | &nbsp;&nbsp;Director | &nbsp;&nbsp;Coastal Building, Wickham's, Cay II, P.O. Box 2221, Road Town, Tortola, VIRGIN ISLANDS, BRITISH | &nbsp;&nbsp;VIRGIN ISLANDS, BRITISH |
| &nbsp;&nbsp;Ronel Anneli Williams | &nbsp;&nbsp;Authorized signatory of Control Services Corp. | &nbsp;&nbsp;Irvine's Place, 159 Main Street, 1st Floor, PO Box 2132, Road Town, Tortola, British Virgin Islands, VG 1110 | &nbsp;&nbsp;MAURITIUS |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**PSYENCE BIOMEDICAL LTD.**

*(Name of Issuer)*

**Common Shares, no par value**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Adri Botha**<br>Psyence Labs Ltd., Irvines Place,<br>159 Main Street, 1st Floor, PO Box 2132<br>Road Town, Tortola D8 VG1110<br>230 405-9005

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**02/25/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Psyence Labs Ltd.** | Name of reporting person<br>**Psyence Labs Ltd.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1146159.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1146159.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1146159.00** | Aggregate amount beneficially owned by each reporting person<br>**1146159.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**30.05%** | Percent of class represented by amount in Row (11)<br>**30.05%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** (1) Percentage based on 3,814,328 outstanding Common Shares as of June 1, 2026, as reported by the Issuer directly to the Reporting Person.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, no par value

**(b) Name of Issuer:**
PSYENCE BIOMEDICAL LTD.

**(c) Address of Issuer's Principal Executive Offices:**
121 Richmond Street West, Penthouse Suite 1300, Toronto, Ontario, A6, M5H 2K1

**Item 4. Purpose of Transaction**

The Reporting Person acquired the Subject Shares pursuant to the exercise of an irrevocable put option granted to the Reporting Person under the Put Option Agreement. As previously disclosed by the Issuer in its Report on Form 6-K furnished to the Securities and Exchange Commission on February 13, 2026, the Reporting Person exercised the put option to require the Issuer to subscribe for US$5,000,000 of ordinary shares of the Reporting Person, with such subscription consideration to be satisfied through the issuance of Common Shares of the Issuer pursuant to the Share Exchange.

The Reporting Person acquired the Subject Shares for investment purposes. The Reporting Person intends to review its investment in the Issuer on a continuing basis and may, from time to time and at any time, depending on various factors, including, without limitation, the Issuer's financial position and strategic direction, actions taken by the Issuer's board of directors (the "Board"), price levels of the Common Shares, conditions in the securities market, and general economic and industry conditions, take such actions with respect to its investment in the Issuer as it deems appropriate, including, without limitation:

(i) acquiring additional Common Shares and/or other equity, debt, notes, instruments or other securities of the Issuer (collectively, "Securities") in the open market, in privately negotiated transactions, or otherwise; (ii) disposing of any or all of the Securities in the open market, in privately negotiated transactions, or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

Except as set forth in this Schedule 13D, or as may be discussed from time to time between the Reporting Person and the Issuer or other persons, the Reporting Person does not have, as of the date of this filing, any plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, although, subject to the matters described herein, the Reporting Person may, at any time and from time to time, review or reconsider its position and formulate plans or proposals with respect thereto.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person beneficially owns 1,146,159 Common Shares, representing approximately  30.05% of the issued and outstanding Common Shares of the Issuer. The foregoing percentage is calculated based on 3,814,328 outstanding Common Shares as of June 1, 2026.

**(b)**
The Reporting Person has sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of, the 1,146,159 Common Shares reported herein. The Reporting Person does not share voting or dispositive power with respect to any Common Shares.

**(c)**
Except for the acquisition of the Subject Shares pursuant to the Share Exchange as described in Item 3 above, the Reporting Person has not effected any transactions in the Common Shares during the 60 days preceding the date of this Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Items 3 and 4 of this Schedule 13D is hereby incorporated by reference into this Item 6.

The Subject Shares were issued by the Issuer to the Reporting Person in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), pursuant to Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder.

Except as described in this Schedule 13D, including in the Put Option Agreement referenced in Item 3, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any other person with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Psyence Labs Ltd.

**Signature:** /s/ Ronel Anneli Williams

**Name/Title:** Ronel Anneli Williams / Authorized Signatory of Control Services Corp., Director

**Date:** 06/03/2025